ARTEMIS-009: A Phase 3, Randomized, Controlled, Multi-center, Open-label Study of HS-20093 Versus Active Surveillance As Consolidation Therapy After Chemoradiotherapy in Subjects With Limited-Stage Small Cell Lung Cancer
Latest Information Update: 03 Aug 2024
At a glance
- Drugs HS-20093 (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms ARTEMIS-009
- Sponsors Hansoh BioMedical R&D Company
Most Recent Events
- 03 Aug 2024 New trial record